Drug Type Antibody drug conjugate (ADC) |
Synonyms ABBV-221, ABBV221 |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | US | 09 Jan 2015 | |
Advanced Malignant Solid Neoplasm | Phase 1 | ES | 09 Jan 2015 | |
Colorectal Cancer | Phase 1 | US | 09 Jan 2015 | |
Colorectal Cancer | Phase 1 | ES | 09 Jan 2015 | |
Glioblastoma Multiforme | Phase 1 | US | 09 Jan 2015 | |
Glioblastoma Multiforme | Phase 1 | ES | 09 Jan 2015 | |
Non-Small Cell Lung Cancer | Phase 1 | US | 09 Jan 2015 | |
Non-Small Cell Lung Cancer | Phase 1 | ES | 09 Jan 2015 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | US | 09 Jan 2015 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | ES | 09 Jan 2015 |
Phase 1 | 45 | lnggebziok(rpydlttoth) = jwkxozribs ejwitgcwcu (xztlmmilwz ) View more | Negative | 01 Oct 2020 | |||
Phase 1 | 42 | wfkdcdfxeq(bmoozuaaix) = kcqlzjxypd bbeqxyvmtj (fgovohdyzg ) | Positive | 30 May 2017 |